Physician profile
Thomas John
NPI 1457351041
$12,711.99
in general payments reported to CMS, 2019-2025
14 companies · $61.07 in 2025
The $61.07 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,204 · 2020: $7,000 · 2021: $124 · 2022: $235 · 2023: $55.22 · 2024: $32.73 · 2025: $61.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $149.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $11,906.86 | 2019-2025 | |
| Astellas Pharma US INC | $227.39 | 2019 | |
| Katena Products, INC. (Dba Corza Medical) | $219.78 | 2022 | |
| Shire North American Group INC | $61.28 | 2019 | |
| Carl Zeiss Meditec, INC. | $57.26 | 2021 | |
| Dompe US, INC. | $56.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $55.40 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $24.18 | 2025 | |
| Aerie Pharmaceuticals, INC. | $20.60 | 2019 | |
| Rayner Intraocular Lenses Limited | $18.43 | 2024 | Rayone Aspheric, Omidria, Rayone Emv |
| Sun Pharmaceutical Industries INC. | $18.13 | 2019 | |
| Vyera Pharmaceuticals, LLC | $16.73 | 2019 | |
| Sight Sciences, INC. | $15.29 | 2021 | |
| Alcon Vision LLC | $14.30 | 2024 | Rocklatan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.